Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

The new line of credit could ease pressure on the money-losing vaccine maker as it tries to chart its post-pandemic future.